The Dynamic Incretin Adaptation and Type 2 Diabetes

The dynamic incretin adaptation and type 2 diabetes.

Incretin agents in type 2 diabetes.

OBJECTIVE To evaluate the emerging classes of antihyperglycemic agents that target the incretin pathway, including their therapeutic efficacy and side effect profiles, in order to help identify their place among the treatment options for patients with type 2 diabetes. QUALITY OF EVIDENCE MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews were searched. Most evidence is level I a...

Incretin-based Therapy in the Management of Type 2 Diabetes

Type 2 diabetes is a progressive disease due to reduced beta cell mass, which results in the failure of traditional treatment and the need for more intensive therapeutical measures to maintain a good glycaemic control. Within the last decade there was a preoccupation for developing new classes of drugs to achieve several goals: glycaemic control, weight loss and to preserve residual beta cell m...

Enhancing incretin action for the treatment of type 2 diabetes.

OBJECTIVE To examine the mechanisms of action, therapeutic potential, and challenges inherent in the use of incretin peptides and dipeptidyl peptidase-IV (DPP-IV) inhibitors for the treatment of type 2 diabetes. RESEARCH DESIGN AND METHODS The scientific literature describing the biological importance of incretin peptides and DPP-IV inhibitors in the control of glucose homeostasis has been re...

Incretin System in the Pathogenesis of Type 2 Diabetes and the Role of Incretin Based Therapies in the Management of Type 2 Diabetes